Chronic sacral nerve stimulation prevents detrusor structural and functional changes associated with bladder outlet obstruction - A rat model

Neurourology and Urodynamics

Volumn 29, Issue 5, 2010, Pages 783-788

  Comiter, Craig V ^a   Mazar, Carla ^b   Phull, Hardeep ^a   Salkini, Mohamad ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Animal model; Benign prostatic obstruction; Neuromodulation; Urodynamics

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CAPACITY; BLADDER NECK STENOSIS; CONTROLLED STUDY; DETRUSOR MUSCLE; DISEASE ASSOCIATION; DORSAL ROOT; FEMALE; FIBROSIS; HYPERTROPHY; LUMBOSACRAL PLEXUS; NERVE STIMULATION; NEUROMODULATION; NONHUMAN; RAT; SCORING SYSTEM; URETHRA OBSTRUCTION; URODYNAMICS;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION THERAPY; FEMALE; LUMBOSACRAL PLEXUS; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER DISEASES; URINARY BLADDER NECK OBSTRUCTION;

EID: 77956851007     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20820     Document Type: Article

References (25)

1. Collado A, Batista E, Gelabert-Mas A, et al. Detrusor quantitative morphometry in obstructed males and controls. J Urol 2006;176:2722-2728.
2. Abdel-Aziz KF, Lemack GE. Overactive bladder in the male patient: bladder outlet, or both? Curr Urol Rep 2002;3:445-451.
3. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocer plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169: 2253-2256.
4. Abrams P, Kaplan SA, DeKoning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175:999-1004.
5. Chancellor MB, Chartier-Kastler EJ. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromodulation 2000;3:15-26.
6. Van BalkenMR, Vergunst H, Bemelmans BLH. The use of electrical devices for the treatment of bladder dysfunction: a review of methods. J Urol 2004;172: 846-851.
7. Lycklama a Nijeholt AAB, Groenendijk PM, den Boon J. Clinical and urodynamic assessments of the mode of action of sacral nerve stimulation. In: Jonas U, Grunewald V, editors. New perspectives in sacral nerve stimulation for control of lower urinary tract dysfunction. London: Martin Dunitz Ltd; 2002. pp. 43-54.
8. Beamon CR, Mazar C, Salkini M, et al. The effect of sildenafil citrate on bladder outlet obstruction: a mouse model. BJU Int 2009;. In press.
9. Matsumoto S, Hanai T, Ohnishi N, et al. Bladder smooth muscle cell phenotypic changes and implication of expression of contractile proteins (especially caldesmon) in rats after partial outlet obstruction. Int J Urol 2003;10:339-345.
10. Lee KS, Choo MS, Kim Dy, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005;174:1334-1338.
11. Zhang EY, Stein R, Chang S, et al. Smooth muscle hypertrophy following partial bladder outlet obstruction is associated with overexpression of nonmuscle caldesmon. Am J Pathol 2004;164:601-612.
12. Brading AF, Turner WH. The unstable bladder: towards a common mechanism. BJU 1994;73:3-8.
13. Price DA, Ramsden PD, Stobbart D. The unstable bladder and prostatectomy. BJU 1980;52:529-531.
14. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a roandomized controlled trial. JAMA 2006;296:2319-2328.
15. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-1407.
16. Mulhall JP, Guhring P, Parker M, et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-667.
17. Kimm S, Mazar C, Salkini M, et al. Solifenacin succinate prevents urodynamic and detrusor changes associated with bladder outlet obstruction-a mouse model. J Urol 2009;181:693.
18. Sullivan MP, DuBeau CE, Resnick NM, et al. Continuous occlusion test to determine detrusor contractile performance. J Urol 1995; 1834-1840.
19. Persson K, Pandita RK, Waldeck K, et al. Angiotensin II and bladder obstruction in the rat: influence on hypertrophic growth and contractility. AJP 1996;271:R1186-R1192.
20. Greenland JE, Hvistendahl JJ, Andersen H, et al. The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder. BJU Int 2000;85:1109-1114.
21. Azodzoi KM, Keim VK, Tarcan T, et al. Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanoids. Neurourol Urodyn 2004;23:258-264.
22. Chancellor MB, Chartier-Kastler EJ. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromodulation 2000;3:15-26.
23. Van Kerrebroeck PEV. The role of electrical stimulation in voiding dysfunction. Eur Urol 1998;34:27-30.
24. Van Balken MR, Vergunst H, Bemelmans BLH. The use of electrical devices for the treatment of bladder dysfunction: a review of methods. J Urol 2004; 172:846-851.
25. Fillippi S, Morelli a, Sandner P, Fibbi B, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-1029.